WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

In vitro Non-Alcoholic Steatohepatitis (NASH) Services

Fast-track NASH drug discovery with organ-on-a-chip studies


Our Non-Alcoholic Fatty Liver Disorder (NAFLD)/NASH in vitro Services offer a preclinical tool to test therapeutics in a human-relevant model, replicating key disease phenotypes including fibrosis and reporting clinical biomarkers to allow translatability to clinical trials. 

NASH in vitro services overview:

We offer a collaborative approach, applying our extensive NASH expertise to designing an experiment that best suits your needs. Our established Liver-on-a-chip NAFLD/NASH assay can be adapted to investigate specific questions, focus on different endpoints, or provide samples for -omics analysis. 

  • Explore or validate the effect of your therapeutic in an industry-validated model
  • Uses validated cells with known NASH-related genotypes
  • Capture clinical markers with proven translatability
  • Assess inflammation, fibrosis, steatosis, and cell health biomarkers
  • Option to add -omics analysis of samples
  • Full project report detailing methods and results and all raw data

Customer feedback

Working with CN Bio has been a pleasure, the team listened to our non-trivial requirements and made useful suggestions to help meet objectives. During the course of the project, the team were responsive and helpful. The results were delivered as agreed and helped us to move towards our goals.

Dr Giuseppe Ferrandino

Senior Translational Scientist at Owlstone Medical

View more PhysioMimix reviews on SelectScience

Dr Giuseppe Ferrandino photo

Inipharm is developing a drug that targets a genetic metabolic target which has metabolomics differences between mice and men.  For this reason, we evaluated several different primary human testing systems that have features of NASH. We found CN Bio has developed a system that has steatotic, inflammatory, and fibrotic features that have been very useful in evaluating our lead compounds. The scientists at CN Bio are very knowledgeable and have worked with us on the study details to obtain the best quality of results in a timely manner.

Heather Hsu

Chief Scientific Officer, Inipharm

View more PhysioMimix reviews on SelectScience

How the service works:

Through the co-culture of primary human hepatocytes and non-parenchymal cells and the evaluation of multiple endpoints, our assay offers a complete assessment of NASH drug efficacy.

This service generates human-relevant data that captures the key pathophysiology of NASH, providing a complementary approach to murine models.

Your dedicated contact will work collaboratively with you from the start to the end of the project.

  1. Design and finalize experiment plan 
  2. Customer supplies required amount of drug(s)
  3. Three to four weeks to complete cell culture  
  4. Two to three weeks to run endpoint assays, analyze data and complete the report 
  5. ~ two months to complete the study from receiving an order 

Standard NASH cell culture timeline

a Standard NASH cell culture timeline

Endpoint measurements

milti chip plates |

Included, but are not limited to:

Functionality biomarkers

  • Albumin production
  • Urea production

Clinical liver heath biomarkers

  • Lactose dehydrogenase (LDH) release
  • Aspartate Transferase (AST)/Alanine amino transferase (ALT)

Disease biomarkers

  • Luminex®/ELISA assays
    • Fibrosis (e.g. TIMP-1, Pro-collagen, Fibronectin)
    • Inflammation (e.g. IL-6, IL-8 TNF-α)
  • Confocal microscopy
    • Smooth muscle actin
    • Collagen
    • Fat accumulation (Nile Red staining)

Related applications

NASH cell imagery

Non-alcoholic steatohepatitis

With anti-NASH therapeutics failing to pass clinical trials, a new preclinical test is required to improve human efficacy predictions. Our NAFLD/NASH application provides a pre-clinical in vitro model using human tissue to fully replicate this critical liver disease phenotype.

Learn more
tube an pipette close up

Learn more about our NAFLD / NASH in vitro Services

Request more info

Featured resources

Scientific publications

Bone morphogenetic |

Bone morphogenetic protein 8B promotes the progression of Non-Alcoholic Steatohepatitis

Scientific publications

Modelling human liver fibrosis |

Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system

Scientific publications

B2 Spectrin 2021 Graphic |

β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development

View all NAFLD / NASH related resources

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023